Keisuke Horikawa received his M.D. from Chiba University Graduate School of Medicine and Ph.D. from the Institute of Medical Science, the University of Tokyo under the supervision of Dr. Tadashi Yamamoto. After postdoctoral research training in the Kiyoshi Takasu's laboratory at the University of Tokyo, he continued his postdoctoral fellow at the Department of Genome Sciences Lab, John Curtin School of Medical Research, the Australian National University. Currently, he serves as a group leader in the Department of Cancer Biology and Therapeutics at the Australian National University. He has been studyingthe analysis of ubiquitination and protein degradation functions in dendritic cells, elucidation of autoantibody production mechanisms through CARD11 mutations in human lymphoma, and analysis of Toll-like receptor signaling molecules and Myd88 mutations in human diffuse large B-cell lymphoma.